Bio Plus Co

Bio Plus Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Bio Plus Co (099430.KQ) as of Oct 24, 2026 is -0.13. In the previous year, Net Debt to Free Cash Flow Ratio was 0.50 — a change of -126.06% (lower).

Net Debt/FCF

-0.13

YoY

-126.06%

Last updated:

Net Debt to Free Cash Flow Ratio of Bio Plus Co is 2025 -0.13 . Net Debt to Free Cash Flow Ratio of Bio Plus Co was 2024 0.50 . It decreases by -126.06% lower compared to the previous year.

The Bio Plus Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
0.00 KRW
Jan 1, 2019
1.81 KRW
Jan 1, 2020
-1.78 KRW
Jan 1, 2021
20.28 KRW
Jan 1, 2022
-10.91 KRW
Jan 1, 2023
10.17 KRW
Jan 1, 2024
0.50 KRW
Jan 1, 2025
-0.13 KRW
The Bio Plus Co Net Debt/FCF history
YEARNet Debt/FCFYoY
-0.13-126.06%
0.50-95.12%
10.17-193.14%
-10.91-153.83%
20.28-1,237.00%
-1.78-198.73%
1.81+40,677.06%
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Net Debt to Free Cash Flow Ratio of Bio Plus Co is -0.13 in 2025.

Net Debt to Free Cash Flow Ratio of Bio Plus Co changed from 0.50 to -0.13, representing a -126.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bio Plus Co

All Key Metrics — Bio Plus Co